This is a preview of subscription content, log in via an institution to check access.
Data sharing and data availability
Data sharing is not applicable to this article as no new data were created or analyzed.
References
Taher AT, Musallam KM, Cappellini MD (2021) beta-Thalassemias. N Engl J Med 384:727–743
Musallam KM, Bou-Fakhredin R, Cappellini MD, Taher AT (2021) 2021 update on clinical trials in beta-thalassemia. Am J Hematol 96:1518–1531
Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ, Thalassemia Clinical Research N (2012) Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 119:2746–2753
Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, Kwiatkowski J, Thompson AA, Porter J, Coates T, Giardina PJ, Olivieri N, Yamashita R, Neufeld EJ, Thalassemia Clinical Research N (2011) Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol 86:433–436
Forni GL, Gianesin B, Musallam KM, Longo F, Rosso R, Lisi R, Gamberini MR, Pinto VM, Graziadei G, Vitucci A, Bonetti F, Musto P, Piga A, Cappellini MD, Borgna-Pignatti C, Webthal P (2023) Overall and complication-free survival in a large cohort of patients with beta-thalassemia major followed over 50 years. Am J Hematol 98:381–387
Musallam KM, Vitrano A, Meloni A, Pollina SA, Karimi M, El-Beshlawy A, Hajipour M, Di Marco V, Ansari SH, Filosa A, Ricchi P, Ceci A, Daar S, Vlachaki E, Singer ST, Naserullah ZA, Pepe A, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A, International Working Group on T (2022) Risk of mortality from anemia and iron overload in nontransfusion-dependent beta-thalassemia. Am J Hematol 97:E78–E80
Musallam KM, Vitrano A, Meloni A, Addario Pollina S, Di Marco V, Hussain Ansari S, Filosa A, Ricchi P, Ceci A, Daar S, Vlachaki E, Singer ST, Naserullah ZA, Pepe A, Scondotto S, Dardanoni G, Karimi M, El-Beshlawy A, Hajipour M, Bonifazi F, Vichinsky E, Taher AT, Sankaran VG, Maggio A, International Working Group on T (2022) Primary HBB gene mutation severity and long-term outcomes in a global cohort of beta-thalassaemia. Br J Haematol 196:414–423
Musallam KM, Cappellini MD, Daar S, Taher AT (2022) Morbidity-free survival and hemoglobin level in non-transfusion-dependent beta-thalassemia: a 10-year cohort study. Ann Hematol 101:203–204
Funding
The AD-TLC is funded through the Department of Health in Abu Dhabi.
Author information
Authors and Affiliations
Contributions
All authors contributed to manuscript drafting or critical review and final approval for submission.
Corresponding author
Ethics declarations
Ethical approval
The AD-TLC is approved by the Abu Dhabi Health Research and Technology Ethics Committee, approval number DOH/CVDC/2022/1808.
Conflict of interest
K. M. M. has been or is a consultant for Novartis, Celgene Corp (Bristol Myers Squibb), Agios Pharmaceuticals, CRISPR Therapeutics, Vifor Pharma, and Pharmacosmos. The remaining authors have no conflicts of interest to disclose.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Musallam, K.M., Ahmed, W., Almarshoodi, M.O. et al. Establishment of the Abu Dhabi Emirate Thalassemia Longitudinal Cohort (AD-TLC): leveraging the power of observation. Ann Hematol 102, 2277–2278 (2023). https://doi.org/10.1007/s00277-023-05252-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-023-05252-z